Neripar (Linagliptin)

Linagliptin, the active ingredient in Neripar, is a DPP-4 inhibitor presented as a tablet for oral use. It helps lower blood glucose in adults with type 2 diabetes mellitus. GNH USA supplies Neripar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is used to improve glycemic control in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels when combined with diet and exercise. - Monotherapy in type 2 diabetes: provides glucose‑lowering effect for patients inadequately controlled by lifestyle alone. - Combination therapy: used alongside metformin, sulfonylureas or insulin to achieve target HbA1c.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headed sensation. - Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea. - Back pain: occasional musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity: rash, angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Severe allergic reactions: respiratory distress or shock.

Linagliptin should be used with clinical monitoring and awareness of patient‑specific factors. - Renal impairment: assess kidney function before initiation and periodically thereafter. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Linagliptin may interact with several medicines that affect its plasma concentration or glycaemic response.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure. - Combination with insulin or sulfonylureas: heightened risk of hypoglycaemia. - Rifampin: may reduce linagliptin efficacy.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure and renal function. - Diuretics: observe electrolyte balance. - Warfarin: check INR regularly for potential anticoagulant effect changes.